SkinBioTherapeutics Cash Flow Statement

Financials in millions GBP. Fiscal year is July - June.

Millions GBP. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	2018 - 2016
Period Ending	Dec '23 Dec 31, 2023	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020	Jun '19 Jun 30, 2019	2018 - 2016
Net Income	-2.88	-2.84	-2.79	-1.43	-1.5	-1.15	Upgrade
Depreciation & Amortization	0.08	0.05	0.04	0.01	0.01	0	Upgrade
Stock-Based Compensation	-0.02	0	0.05	0.06	0.16	0.08	Upgrade
Other Operating Activities	0.01	0.08	-0.08	-0.07	0.09	-0.12	Upgrade
Change in Accounts Receivable	-0.03	-0.05	0.13	-0.2	0.17	-0.15	Upgrade
Change in Inventory	0.04	0.09	-0.12	-	-	-	Upgrade
Change in Accounts Payable	-0.2	0.02	0.1	0.07	0.18	-0.09	Upgrade
Operating Cash Flow	-3.02	-2.65	-2.67	-1.56	-0.89	-1.43	Upgrade
Capital Expenditures	-0.1	-0.09	-	-	-	-0.01	Upgrade
Sale (Purchase) of Intangibles	-0.11	-0.08	-0.1	-0.11	-0.07	-0.06	Upgrade
Other Investing Activities	-	-	-	-0	-	-	Upgrade
Investing Cash Flow	-0.21	-0.17	-0.1	-0.11	-0.07	-0.07	Upgrade
Long-Term Debt Repaid	-	-0.04	-0.04	-0	-	-	Upgrade
Net Debt Issued (Repaid)	-0.04	-0.04	-0.04	-0	-	-	Upgrade
Issuance of Common Stock	5.61	2.62	-	4.12	-	1.5	Upgrade
Other Financing Activities	-0.26	-0.26	-	-	-	-0.06	Upgrade
Financing Cash Flow	5.31	2.32	-0.04	4.12	-	1.44	Upgrade
Net Cash Flow	2.07	-0.49	-2.8	2.45	-0.97	-0.06	Upgrade
Free Cash Flow	-3.12	-2.73	-2.67	-1.56	-0.89	-1.44	Upgrade
Free Cash Flow Margin	-1931.00%	-2071.02%	-3575.44%	-	-	-	Upgrade
Free Cash Flow Per Share	-0.02	-0.02	-0.02	-0.01	-0.01	-0.01	Upgrade
Cash Income Tax Paid	-	-0.26	-0.12	-	-0.21	-0.09	Upgrade
Levered Free Cash Flow	-2.25	-1.86	-1.85	-1.17	-0.48	-1.2	Upgrade
Unlevered Free Cash Flow	-2.25	-1.85	-1.84	-1.17	-0.48	-1.2	Upgrade
Change in Net Working Capital	0.19	-0.14	-0.03	0.19	-0.45	0.36	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.